Start all patients on statins early after PCI

Adrian W. Messerli; Herbert D. Aronow; Dennis L. Sprecher

doi:10.3949/ccjm.70.6.561

Start all patients on statins early after PCI

Adrian W. Messerli, Herbert D. Aronow, Dennis L. Sprecher

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

The Lescol Intervention Prevention Study (LIPS) was the first randomized trial to show a significant reduction in the risk of cardiac events in patients started on fluvastatin immediately after a successful percutaneous coronary intervention. The benefit was independent of baseline cholesterol levels. The results suggest that all patients should be discharged on lipid-lowering therapy after a percutaneous coronary intervention. Currently, this is seldom done.

Original language	English
Pages (from-to)	561-566
Number of pages	6
Journal	Cleveland Clinic Journal of Medicine
Volume	70
Issue number	6
DOIs	https://doi.org/10.3949/ccjm.70.6.561
State	Published - Jun 1 2003

ASJC Scopus subject areas

General Medicine

Access to Document

10.3949/ccjm.70.6.561

Cite this

@article{8c0b4d8e0c084b4094867a721179811c,

title = "Start all patients on statins early after PCI",

abstract = "The Lescol Intervention Prevention Study (LIPS) was the first randomized trial to show a significant reduction in the risk of cardiac events in patients started on fluvastatin immediately after a successful percutaneous coronary intervention. The benefit was independent of baseline cholesterol levels. The results suggest that all patients should be discharged on lipid-lowering therapy after a percutaneous coronary intervention. Currently, this is seldom done.",

author = "Messerli, \{Adrian W.\} and Aronow, \{Herbert D.\} and Sprecher, \{Dennis L.\}",

year = "2003",

month = jun,

day = "1",

doi = "10.3949/ccjm.70.6.561",

language = "English",

volume = "70",

pages = "561--566",

number = "6",

}

TY - JOUR

T1 - Start all patients on statins early after PCI

AU - Messerli, Adrian W.

AU - Aronow, Herbert D.

AU - Sprecher, Dennis L.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - The Lescol Intervention Prevention Study (LIPS) was the first randomized trial to show a significant reduction in the risk of cardiac events in patients started on fluvastatin immediately after a successful percutaneous coronary intervention. The benefit was independent of baseline cholesterol levels. The results suggest that all patients should be discharged on lipid-lowering therapy after a percutaneous coronary intervention. Currently, this is seldom done.

AB - The Lescol Intervention Prevention Study (LIPS) was the first randomized trial to show a significant reduction in the risk of cardiac events in patients started on fluvastatin immediately after a successful percutaneous coronary intervention. The benefit was independent of baseline cholesterol levels. The results suggest that all patients should be discharged on lipid-lowering therapy after a percutaneous coronary intervention. Currently, this is seldom done.

UR - http://www.scopus.com/inward/record.url?scp=0041842664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041842664&partnerID=8YFLogxK

U2 - 10.3949/ccjm.70.6.561

DO - 10.3949/ccjm.70.6.561

M3 - Article

C2 - 12828227

AN - SCOPUS:0041842664

SN - 0891-1150

VL - 70

SP - 561

EP - 566

JO - Cleveland Clinic Journal of Medicine

JF - Cleveland Clinic Journal of Medicine

IS - 6

ER -

Start all patients on statins early after PCI

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this